VIVEVE MED INC
VIVE
VIVE was delisted on the 18th of January, 2023.
49 hedge funds and large institutions have $68.1M invested in VIVEVE MED INC in 2017 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 21 increasing their positions, 7 reducing their positions, and 6 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 7
67% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 6
7% more funds holding
Funds holding: 46 → 49 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
25% less capital invested
Capital invested by funds: $91.2M → $68.1M (-$23.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$1.46M |
| 2 |
RI
RTW Investments
New York
|
+$1.44M |
| 3 |
JGC
J. Goldman & Co
New York
|
+$1.11M |
| 4 |
IG
ING Group
Amsterdam,
Netherlands
|
+$968K |
| 5 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$721K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MHP
Manatuck Hill Partners
Westport,
Connecticut
|
-$2.87M |
| 2 |
PA
Perceptive Advisors
New York
|
-$2.48M |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
-$790K |
| 4 |
1CM
1492 Capital Management
Milwaukee,
Wisconsin
|
-$382K |
| 5 |
JP Morgan Chase
New York
|
-$123K |
VIVE Hedge Fund Activity: Q3 2017 in Review
49 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in VIVEVE MED INC (VIVE) for Q3 2017, worth a combined $68.1M — down 25% from $91.2M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new VIVE positions and 6 closed out — a net gain of 4 holders — while 21 added to existing stakes and 7 trimmed.
The largest buyer was Avoro Capital Advisors, adding an estimated $1.46M. The largest seller was Manatuck Hill Partners, exiting entirely with an estimated $2.87M sold.
- 49 institutional investors held VIVEVE MED INC (VIVE) as of Q3 2017, up from 46 in Q2 2017.
- Funds reported $68.1M of VIVEVE MED INC stock for Q3 2017, down 25% quarter-over-quarter.
- 10 funds opened new VIVEVE MED INC positions in Q3 2017 and 6 closed out, a net change of +4 holders.
- The largest VIVEVE MED INC buyer in Q3 2017 was Avoro Capital Advisors, an estimated $1.46M added.
- The largest VIVEVE MED INC seller in Q3 2017 was Manatuck Hill Partners, an estimated $2.87M sold.
Based on aggregated 13F filings for Q3 2017.